Objective: To investigate the clinical value of Fuzheng Yiai Decoction (FZYAD) in postoperational large intestinal Cancer after treatment.
Methods: Thirty-eight cases treated by FZYAD combined with chemotherapy in the treated group were observed and compared with 30 patients in the control group treated with chemotherapy alone.
Results: After treatment, patients' physical strength of the treated group was better than that of the control group (P < 0.01), meanwhile, the median survival time was longer (31.4 months vs 18 months, P < 0.01), the survival rate higher (P < 0.05), and the recurrence rate lower (21.05% vs 48.34%, P < 0.05) in comparison of the treated group and the control group. Moreover, the cellular immune function of the treated group was improved after treatment.
Conclusions: In treatment of postoperational large intestinal cancer, the effect of FZYAD combined chemotherapy is better than that of chemotherapy alone in immune function regulation, cancer inhibition, relapse prevention and survival time prolongation.